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Abstract
Encephalopathy is an important complication associated with influenza, most frequently observed 
in young children, with a wide range of severity. The most severe category of influenza-associated 
encephalopathy (IAE) is acute necrotizing encephalopathy (ANE), characterized by high 
frequency of neurologic sequelae and fatal outcomes. We report two young siblings who 
developed fever and seizures with altered mental status. Influenza A(H1N1)pdm09 virus infection 
was identified in upper respiratory tract specimens from both patients, and neuroimaging revealed 
bilateral inflammatory lesions, consistent with acute necrotizing encephalopathy. Neither child had 
received influenza vaccination. Both children progressed to critical illness and required invasive 
mechanical ventilation. In addition to critical care management, both patients received high-dose 
corticosteroids, mannitol, anticonvulsants, and antiviral treatment of influenza. The older child 
recovered fully and was discharged 2 weeks after illness onset, but the younger sibling developed 
severe brainstem edema and cerebellar tonsillar herniation, and died on illness day 11. Both 
children tested positive for Ran Binding Protein 2 (RANBP2) gene mutations. RANBP2 is a 
genetic polymorphism associated with recurrent episodes of necrotizing encephalitis with 
respiratory viral infections. Annual influenza vaccination is especially important for ANE 
survivors, with or without RANBP2 mutations, their household contacts, and caregivers. During 
influenza season, close monitoring of any child with a history of neurological complications 
associated with respiratory illness is indicated, with prompt initiation of antiviral treatment with 
onset of acute respiratory illness, and influenza testing performed by molecular assay.
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Encephalopathy is a severe influenza-associated complication and has been described most 
frequently in young children, particularly in Japan [1–3]. The onset of influenza-associated 
encephalopathy (IAE) typically occurs within a few days of the onset of influenza signs and 
symptoms, and the outcomes range from full recovery to neurologic sequelae in survivors or 
to fulminant progression and brain death [1–3]. IAE is distinct from Reye syndrome and not 
associated with salicylate exposure; although the transaminase level can be elevated, 
hypoglycemia and hyperammonemia are uncommon [1, 2]. Acute necrotizing 
encephalopathy (ANE) of childhood, the most severe form of IAE, first described in Japan 
in 1995, is characterized by sudden onset of fever, convulsions, coma, and sometimes death; 
symmetric inflammatory brain lesions are noted on neuroimaging [4].
IAE has been reportedly associated with influenza A, B, and C virus infections of the 
respiratory tract that can trigger a dys-regulated host cytokine response [5–9]. Before the 
2009 H1N1 pandemic, sporadic cases of IAE, including ANE with fatal outcome, were 
reported infrequently in the United States [10–13]. During the 2009 pandemic, a large 
increase in pediatric IAE cases associated with influenza A(H1N1)pdm09 virus infection 
was noted in Japan [3]. Sporadic cases of influenza A(H1N1) pdm09–associated IAE in 
children have been reported in the United States and worldwide [14–17]. Here, we report 
cases of IAE with ANE that occurred concurrently in 2 young siblings, from 
nonconsanguineous parentage, who were heterozygous for a missense mutation in the 
nuclear pore protein Ran-binding protein 2 gene (RANBP2); mutations in RANBP2 have 
been linked to infection-triggered familial and recurrent ANE [18]
CASE REPORTS
Case 1
A 5-year-old boy in Mexico with a history of complex febrile seizures since the age of 2 
years developed fever up to 39.4°C and cough in January 2017, and he received outpatient 
treatment with oral antibiotics for pharyngitis and ibuprofen for fever. He experienced 
nausea, emesis, and nonbloody diarrhea over the following 2 days. On illness day 4, he 
developed seizures and altered mental status and was admitted to the pediatric intensive care 
unit (PICU) of hospital A. Two prolonged generalized tonic-clonic seizures were observed, 
and anticonvulsant therapy with intravenous (IV) levetiracetam and IV midazolam was 
started. Electroencephalography results were reportedly abnormal. Computed tomography 
(CT) of his head revealed cerebral edema. Brain magnetic resonance imaging (MRI), 
performed 2 days later, revealed bilateral temporal lobe lesions with sub-cortical white 
matter lesions, consistent with encephalitis. Mannitol and methylprednisolone (1 g/24 hours) 
were administered. A lumbar puncture yielded no white blood cells, and Gram-staining 
results were negative. An upper respiratory tract specimen tested positive for influenza A 
viral antigen, and oral oseltamivir treatment was started on illness day 4. Other admission 
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laboratory testing results are listed in Table 1. The patient had received all recommended 
routine childhood immunizations except for the influenza vaccine.
On illness day 8, the patient was transferred to the emergency department of hospital B, 
where he was noted to have a Glasgow Coma Scale score of 7; he was placed on invasive 
mechanical ventilation. Radiography of his chest revealed bilateral infiltrates. A head CT 
scan revealed bilateral decreased attenuation involving the capsule area. Later that day, he 
was transferred to the PICU of hospital C, where a neurological examination revealed intact 
pupillary light and gag reflex. Inotropic support was required for his bradycardia and 
occasional hypotension. He was started on IV vancomycin, IV ceftriaxone, and oral 
oseltamivir. His hepatic transaminase levels and results of his coagulation studies were all 
within their reference range (Table 1). His initial white blood cell count was 7500/μL with 
70% neutrophils and 22% lymphocytes. A repeat head CT scan performed after his 
admission to hospital C revealed symmetric areas of decreased attenuation in the external 
capsules and inferior temporal lobes bilaterally, with partial effacement of the cortical sulci. 
Electroencephalography revealed bilateral parietal spike activity. A nasopharyngeal swab 
tested positive for influenza A(H1N1)pdm09 viral RNA in a multiplex respiratory pathogen 
panel (BioFire Diagnostics, Salt Lake City, Utah). Results of brain MRI performed on illness 
day 9 were significant for bilaterally symmetric restricted diffusion and extensive diffuse 
signal abnormalities along the external capsules, medial temporal lobes, and pons, consistent 
with ischemia/infarction (Figure 1). Levetiracetam was continued for the necrotizing 
encephalitis diagnosis. Oral oseltamivir was discontinued, and IV peramivir was started. 
Antibiotics were discontinued, and he received 1 dose of IV immunoglobulin (1 g/kg) and 
was started on methylprednisolone (30 mg/kg per day); after 4 days, he was switched to 
prednisolone (2 mg/kg per day) for an additional 3 days. The results of bacterial cultures of 
blood, urine, and tracheal aspirate specimens obtained on admission were negative.
His neurological status improved, and he was extubated on illness day 10 and transferred to 
the general inpatient floor on room air for additional monitoring and physical therapy and to 
complete a 5-day course of IV peramivir. On illness day 14, his neurological examination 
was normal, quadrivalent inactivated influenza vaccine was administered, and the patient 
was discharged to his home on levetiracetam anticonvulsant therapy. Blood obtained for 
genetic testing (Fulgent Diagnostics, Temple City, California) revealed a missense mutation 
(c.1754C→T p.Thr585MET) heterozygous for RANBP2.
Case 2
A previously healthy 17-month-old girl, the sister of the boy described in case 1, had fever 
onset of 40°C, eye deviation, and several episodes of focal seizure-like activity in January 
2017. The patient had received all recommended routine childhood immunizations except 
for the influenza vaccine. Her parents denied that the child had any antecedent respiratory 
symptoms. She was admitted to hospital A on the same day as her brother and was 
transferred to the PICU with a clinical diagnosis of encephalitis and influenza, despite 
negative influenza antigen testing results on an upper respiratory specimen; she was started 
on empiric oseltamivir treatment. Diarrhea and vomiting were noted. Twelve hours after 
admission, her seizures reoccurred and IV levetiracetam was administered. Brain MRI 
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revealed multiple hypodense lesions in the limbic region, hippocampus, and frontal lobe 
with severe brainstem edema. Methylprednisolone (1 g/24 hours) and mannitol were 
administered. The patient was intubated for respiratory failure with associated anisocoria 
and decerebrate posturing.
On illness day 5, the patient was transferred to hospital B and then transferred to hospital C 
later that day. The physical examination on admission was significant for mechanical 
ventilation without sedation and absent pupillary, corneal, and gag reflexes, but withdrawal 
to pain was noted. A head CT scan revealed diffuse effacement of the sulci and basilar 
cisterns. A chest CT scan revealed atelectasis or infiltrate in the left lingula. Empiric 
acyclovir, oseltamivir, vancomycin, and ceftriaxone were administered. Laboratory study 
results were remarkable for a serum sodium level of 170 mmol/L (Table 2). Immediate 
management of diabetes insipidus with vasopressin was started, and levetiracetam was 
continued for seizure management. A nasopharyngeal swab tested positive for influenza 
A(H1N1)pdm09 viral RNA via a multiplex respiratory pathogen panel (BioFire 
Diagnostics), and peramivir was continued in place of oseltamivir. Brain MRI results were 
markedly abnormal; severe brainstem edema and cerebellar tonsillar herniation, bilateral 
severe hemorrhagic and edematous thalami, bilateral signal abnormalities in the external 
capsules and medial temporal lobes, and increased signal in the left parietal lobe were seen 
(Figures 2 and 3). The results of bacterial cultures of blood, urine, and tracheal aspirate 
specimens obtained on admission were negative. The child died on illness day 11. Genetic 
testing of her blood revealed a missense mutation (c.1754C→T p.Thr585MET) 
heterozygous for RANBP2.
DISCUSSION
We report here the cases of 2 siblings with severe concurrent influenza A(H1N1)pdm09 
virus–associated ANE, including 1 surviving child without typical thalamic lesions on 
neuroimaging. Neither sibling had a history of salicylate exposure or laboratory findings 
consistent with Reye syndrome. Although reports of IAE have been reported worldwide, to 
our knowledge, only 3 previous fatal cases of ANE with influenza A(H1N1)pdm09 virus 
infection in the United States have been reported [17, 19, 20]. The pathogenesis of ANE is 
thought to involve cytokine dysregulation, which can result in systemic inflammation, 
multiorgan injury, vascular leak, brain cell apoptosis, and cerebral edema along with a high 
mortality rate or a large proportion of survivors with neurologic sequelae, particularly in 
young children [21]. In a study of 184 patients with IAE aged <15 years in Japan, 
independent factors associated with death were an AST level of ≥500 U/L, a glucose level of 
≥150 mg/dL, hematuria or proteinuria (as seen with urinalysis), and administration of 
diclofenac sodium [22]. The patient in case 1 did not have any of these poor prognostic 
indicators and recovered, but the patient in case 2 had hyperglycemia and hematuria, and she 
died.
Both siblings tested positive for a RANBP2 gene mutation. Identification of a familial 
autosomal dominant ANE with RANBP2 gene mutations in 19 families worldwide has been 
reported; these mutations are characterized by recurrent rapid onset of ANE triggered by 
viral infections [23]. Other genetic factors have been implicated in patients with ANE and 
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acute encephalopathy with biphasic seizures and late reduced diffusion [21]. The patient in 
case 1 had a history of complex febrile seizures triggered by suspected influenza at the age 
of 2 years. A small study in which 10 patients with ANE and RANBP2 mutations and 9 
patients with familial or recurrent ANE without RANBP2 mutations were compared found 
that patients in the latter group had a worse outcome [24]. Although our findings support 
recommendations for RANBP2 gene mutation testing in ANE survivors [24–26], annual 
influenza vaccination is recommended for all children aged ≥6 months in the United States 
and might be especially important in ANE survivors with or without a RANBP2 mutation, 
their household contacts, and their care-givers [27]. Given the potential for ANE recurrence 
[24–26], close monitoring of children with a history of neurological complications 
associated with respiratory illness is indicated during influenza season along with prompt 
initiation of antiviral treatment with the onset of respiratory illness and influenza testing via 
molecular assay.
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Figure 1. 
T2-weighted sagittal magnetic resonance image showing bilateral enhancement of the 
external capsules in a 5-year-old boy with acute necrotizing encephalopathy.
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Figure 2. 
T2-weighted sagittal magnetic resonance image showing enhancement of the bilateral 
thalami and external capsule in a 17-month-old girl with necrotizing encephalitis.
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Figure 3. 
T2-weighted coronal magnetic resonance image showing enhancement and edema of the 
brainstem in a 17-month-old girl with necrotizing encephalopathy.
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